
Regeneron Faces Class Action Lawsuit Following Failed Melanoma Trial
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals after the company’s late-stage melanoma therapy trial failed to meet primary endpoints, triggering an $11 billion market capitalization collapse and allegations of misleading disclosures to shareholders regarding the drug's efficacy.


























